Recent studies have found that the serum zinc levels were associated with the risk of Parkinson’s disease (PD), but the results were inconsistent. Thus, we conducted a meta-analysis to summarize the evidence from observational studies between them. Pertinent studies were identified by a search in PubMed, Embase, and Web of science up to July, 10, 2016. Standardized mean difference (SMD) and 95% confidence intervals (CI) with random-effect model was used to combine the results. Subgroup analysis and meta-regression were also conducted. Publication bias was estimated using Begg’s regression asymmetry test. A total of 11 articles involving 822 PD patients and 777 healthy controls were included in the meta-analysis. Our meta-analysis results revealed that the serum zinc levels in PD patients were significantly lower than those in health controls (SMD = −0.779, 95%CI = [−1.323, −0.234], P < 0.001). The association was also significant oriental studies (SMD = −1.601, 95%CI = [−2.398, −0.805], P < 0.001). No publication bias was found. The current study indicated that serum zinc levels in PD patients were significantly lower than those in healthy controls.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55(3):259–272
Tanner CM, Goldman SM (1996) Epidemiology of Parkinson’s disease. Neurol Clin 14(2):317–335
Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348(14):1356–1364. doi:10.1056/NEJM2003ra020003
Chen S, Zheng JC (2012) Translational Neurodegeneration, a platform to share knowledge and experience in translational study of neurodegenerative diseases. Translational Neurodegeneration 1(1):1. doi:10.1186/2047-9158-1-1
Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S210–S212. doi:10.1016/s1353-8020(11)70065-7
Sohmiya M, Tanaka M, Tak NW, Yanagisawa M, Tanino Y, Suzuki Y, Okamoto K, Yamamoto Y (2004) Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson’s disease. J Neurol Sci 223(2):161–166. doi:10.1016/j.jns.2004.05.007
Shazia Q, Mohammad ZH, Rahman T, Shekhar HU (2012) Correlation of oxidative stress with serum trace element levels and antioxidant enzyme status in Beta thalassemia major patients: a review of the literature. Anemia 2012:270923. doi:10.1155/2012/270923
Forsleff L, Schauss AG, Bier ID, Stuart S (1999) Evidence of functional zinc deficiency in Parkinson’s disease. Journal of alternative and complementary medicine (New York, NY) 5(1):57–64. doi:10.1089/act.1999.5.57
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. doi:10.1016/j.jclinepi.2009.06.005
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. doi:10.1007/s10654-010-9491-z
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560. doi:10.1136/bmj.327.7414.557
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
Rosenthal L, Schisterman E (2010) Meta-analysis: drawing conclusions when study results vary. Methods in molecular biology (Clifton, NJ) 594:427–434. doi:10.1007/978-1-60761-411-1_30
Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J (2005) A method for meta-analysis of molecular association studies. Stat Med 24(9):1291–1306. doi:10.1002/sim.2010
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 315(7109):629–634
Jiménez-Jiménez FJ, Molina JA, Aguilar MV, Meseguer I, Mateos-Vega CJ, González-Muñoz MJ, De Bustos F, Martínez-Salio A, Ortí-Pareja M, Zurdo M, Martínez-Para MC (1998) Cerebrospinal fluid levels of transition metals in patients with Parkinson’s disease. J Neural Transm 105(4–5):497–505
Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B (2005) Metals and oxidative stress in patients with Parkinson’s disease. Annali dell’Istituto superiore di sanita 41(2):189–195
Qureshi GA, Qureshi AA, Memon SA, Parvez SH (2006) Impact of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy. J Neural Transm Suppl 71:229–236
Gellein K, Syversen T, Steinnes E, Nilsen TI, Dahl OP, Mitrovic S, Duraj D, Flaten TP (2008) Trace elements in serum from patients with Parkinson’s disease—a prospective case-control study: the Nord-Trondelag health study (HUNT). Brain Res 1219:111–115. doi:10.1016/j.brainres.2008.05.002
Nikam S, Nikam P, Ahaley SK, Sontakke AV (2009) Oxidative stress in Parkinson’s disease. Indian Journal of Clinical Biochemistry : IJCB 24(1):98–101. doi:10.1007/s12291-009-0017-y
Ahmed SSSJ, Santosh W (2010) Metallomic profiling and linkage map analysis of early parkinson’s disease: a new insight to aluminum marker for the possible diagnosis. PLoS One 5(6)
Baillet A, Chanteperdrix V, Trocmé C, Casez P, Garrel C, Besson G (2010) The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson’s disease. Neurochem Res 35(10):1530–1537
Fukushima T, Tan X, Luo Y, Wang P, Song J, Kanda H, Hayakawa T, Kumagai T, Kakamu T, Tsuji M, Hidaka T, Mori Y (2013) Heavy metals in blood and urine and its relation to depressive symptoms in Parkinson’s disease patients. Fukushima J Med Sci 59(2):76–80
Younes-Mhenni S, Aissi M, Mokni N, Boughammoura-Bouatay A, Chebel S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G, Sfar MT, Sfar MH (2013) Serum copper, zinc and selenium levels in Tunisian patients with Parkinson’s disease. La Tunisie Medicale 91(6):402–405
Zhao H-W, Lin J, Wang X-B, Cheng X, Wang J-Y, Hu B-L, Zhang Y, Zhang X, Zhu J-H (2013) Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson’s disease. PLoS One 8(12). doi:10.1371/journal.pone.0083060
Verma AK, Keshari AK, Raj J, Kumari R, Kumar T, Sharma V, Singh TB, Srivastava S, Srivastava R (2016) Prolidase-associated trace elements (Mn, Zn, Co, and Ni) in the patients with Parkinson’s disease. Biol Trace Elem Res 171(1):48–53. doi:10.1007/s12011-015-0503-4
Ooi TC, Mohammad NH, Sharif R (2014) Zinc carnosine protects against hydrogen peroxide-induced DNA damage in WIL2-NS lymphoblastoid cell line independent of poly (ADP-ribose) polymerase expression. Biol Trace Elem Res 162(1–3):8–17. doi:10.1007/s12011-014-0153-y
Kara E, Gunay M, Cicioglu I, Ozal M, Kilic M, Mogulkoc R, Baltaci AK (2010) Effect of zinc supplementation on antioxidant activity in young wrestlers. Biol Trace Elem Res 134(1):55–63. doi:10.1007/s12011-009-8457-z
Eide DJ (2011) The oxidative stress of zinc deficiency. Metallomics : Integrated Biometal Science 3(11):1124–1129. doi:10.1039/c1mt00064k
This work was supported by the National Nature Science Foundation of China [grant numbers 8157315, U1204823, and 81573243], Science and Technology Foundation for Innovation Talent of Henan Province [grant number 154200510010], and Dietary Nutrition Research and Education Foundation of Danone [grant number DIC2013-06].
Conflict of Interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Sun, H., Liu, X., Ge, H. et al. Association Between Serum Zinc Levels and the Risk of Parkinson’s Disease: a Meta-Analysis. Biol Trace Elem Res 179, 45–51 (2017). https://doi.org/10.1007/s12011-017-0941-2
- Serum zinc levels
- Parkinson’s disease